<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Almanac of Clinical Medicine</journal-id><journal-title-group><journal-title xml:lang="en">Almanac of Clinical Medicine</journal-title><trans-title-group xml:lang="ru"><trans-title>Альманах клинической медицины</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2072-0505</issn><issn publication-format="electronic">2587-9294</issn><publisher><publisher-name xml:lang="en">Moscow Regional Research and Clinical Institute (MONIKI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">149</article-id><article-id pub-id-type="doi">10.18786/2072-0505-2014-0-33-76-81</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>TOPICAL ARTICLES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ПРОБЛЕМНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">ANTIVIRAL THERAPY IN LIVER CIRRHOSIS</article-title><trans-title-group xml:lang="ru"><trans-title>ПРОТИВОВИРУСНАЯ ТЕРАПИЯ У БОЛЬНЫХ ЦИРРОЗОМ ПЕЧЕНИ</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Bogomolov</surname><given-names>P. O.</given-names></name><name xml:lang="ru"><surname>Богомолов</surname><given-names>П. О.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD, Head of the Hepatology Department, Consulting and Diagnostic Department, MONIKI, Head of the Moscow Regional Hepatoly Center</p></bio><bio xml:lang="ru"><p>канд. мед. наук, зав. гепатологическим отделением консультативно-диагностического отдела МОНИКИ, руководитель Московского областного гепатологического центра.</p></bio><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Matsievich</surname><given-names>M. V.</given-names></name><name xml:lang="ru"><surname>Мациевич</surname><given-names>М. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD, researcher of the Department of Gastroenterology and Hepatology, MONIKI</p></bio><bio xml:lang="ru"><p>канд. мед. наук, науч. сотр. отделения гастроэнтерологии и гепатологии МОНИКИ.</p></bio><email>macievich@gmail.com</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Koblov</surname><given-names>S. V.</given-names></name><name xml:lang="ru"><surname>Коблов</surname><given-names>С. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, physician-gastroenterologist of the Hepatology Department, Consulting and Diagnostic Department, MONIKI</p></bio><bio xml:lang="ru"><p>врач-гастроэнтеролог гепатологического отделения консультативно-диагностического отдела МОНИКИ.</p></bio><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Petrachenkova</surname><given-names>M. Yu.</given-names></name><name xml:lang="ru"><surname>Петраченкова</surname><given-names>М. Ю.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, physician-gastroenterologist of the Hepatology Department, Consulting and Diagnostic Department, MONIKI</p></bio><bio xml:lang="ru"><p>врач-гастроэнтеролог гепатологического отделения консультативно-диагностического отдела МОНИКИ.</p></bio><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kokina</surname><given-names>K. Yu.</given-names></name><name xml:lang="ru"><surname>Кокина</surname><given-names>К. Ю.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, physician-gastroenterologist of the Hepatology Department, Consulting and Diagnostic Department, MONIKI</p></bio><bio xml:lang="ru"><p>врач-гастроэнтеролог гепатологического отделения консультативно-диагностического отдела МОНИКИ</p></bio><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Moscow Regional Research and Clinical Institute (MONIKI)</institution></aff><aff><institution xml:lang="ru">ГБУЗ МО «Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского» (МОНИКИ)</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">61/2 Shchepkina ul., Moscow, 129110, Russian Federation</institution></aff><aff><institution xml:lang="ru">129110, г. Москва, ул. Щепкина, 61/2, Российская Федерация</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2014-06-15" publication-format="electronic"><day>15</day><month>06</month><year>2014</year></pub-date><issue>33</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>32</fpage><lpage>38</lpage><history><date date-type="received" iso-8601-date="2016-02-14"><day>14</day><month>02</month><year>2016</year></date><date date-type="accepted" iso-8601-date="2016-02-14"><day>14</day><month>02</month><year>2016</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2014, Bogomolov P.O., Matsievich M.V., Koblov S.V., Petrachenkova M.Y., Kokina K.Y.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2014, Богомолов П.О., Мациевич М.В., Коблов С.В., Петраченкова М.Ю., Кокина К.Ю.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder xml:lang="en">Bogomolov P.O., Matsievich M.V., Koblov S.V., Petrachenkova M.Y., Kokina K.Y.</copyright-holder><copyright-holder xml:lang="ru">Богомолов П.О., Мациевич М.В., Коблов С.В., Петраченкова М.Ю., Кокина К.Ю.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://almclinmed.ru/jour/article/view/149">https://almclinmed.ru/jour/article/view/149</self-uri><abstract xml:lang="en"><p>Management of patients with liver cirrhosis due to viral hepatitis is complicated; nevertheless, effective treatment is possible in the majority of diagnosed cases. Etiotropic treatment should be initiated as soon as liver cirrhosis is diagnosed. Antiviral therapy is the only evidence-based and justified treatment approach in such patients. Use of hepatoprotectors with doubtful efficacy significantly reduces chances of recovery and increases likelihood of poor outcomes. During the choice of antiviral regimen, considerations must be given to disease etiology and stage as well as liver functional status. Generally accepted scales for staging of liver cirrhosis (e.g. Child-Turcotte-Pugh and MELD) are helpful in the choice of up-to-date therapy regimen, assessment of the disease prognosis and planning of radical interventions.</p></abstract><trans-abstract xml:lang="ru"><p>Несмотря на то что лечение пациентов с циррозом печени вирусной этиологии сопряжено с существенными трудностями, в большинстве выявляемых случаев есть шансы на проведение эффективной терапии. После постановки диагноза цирроза печени незамедлительно должна быть назначена и начата этиотропная терапия. При этом единственным доказанным и оправданным методом лечения является противовирусная терапия. Назначение гепатопротекторов с сомнительной эффективностью у данной категории больных существенно сокращает шансы на излечение, увеличивая вероятность не- благоприятных исходов. Выбор схемы противовирусного лечения напрямую зависит от этиологии заболевания, его стадии и степени компенсации функции печени. Использование для определения стадии цирроза печени общепризнанных шкал, таких как Child – Turcotte – Pugh и MELD, позволяет не только ориентироваться в многообразии современных схем терапии, но и определять прогнозы течения болезни, планировать выбор радикальных методов лечения.</p></trans-abstract><kwd-group xml:lang="en"><kwd>viral cirrhosis</kwd><kwd>modern classification</kwd><kwd>etiology treatment</kwd><kwd>indications</kwd><kwd>the choice of drugs for antiviral therapy</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>цирроз печени вирусной этиологии</kwd><kwd>современная классификация</kwd><kwd>этиотропная терапия</kwd><kwd>показания</kwd><kwd>выбор препаратов противовирусной терапии</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>1. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, BarkerCollo S, Bartels DH, Bell ML, Benjamin EJ, Bennett D, Bhalla K, Bikbov B, Bin Abdulhak A, Birbeck G, Blyth F, Bolliger I, Boufous S, Bucello C; Memish ZA. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095-128.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>2. Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, RoudotThoraval F. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol. 2013;58(3):593-608.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>3. Hoyert DL, Xu J. Deaths: preliminary data for 2011. Natl Vital Stat Rep. 2012;61(6):1-51.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>4. Lieber CS, Weiss DG, Groszmann R, Paronetto F, Schenker S. Veterans Affairs Cooperative Study 391 Group. II. Veterans Affairs Cooperative Study of polyenylphosphatidylcholine in alcoholic liver disease. Alcohol Clin Exp Res. 2003;27(11):1765-72.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>5. Chung GE, Lee JH, Kim YJ. Does antiviral therapy reduce complications of cirrhosis? World J Gastroenterol. 2014;20(23):7306-11.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>6. Fede G, D’Amico G, Arvaniti V, Tsochatzis E, Germani G, Georgiadis D, Morabito A, Burroughs AK. Renal failure and cirrhosis: a systematic review of mortality and prognosis. J Hepatol. 2012;56(4):810-8.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>7. Cholongitas E, Papatheodoridis GV, Vangeli M, Terreni N, Patch D, Burroughs AK. Systematic review: The model for end-stage liver disease – should it replace Child-Pugh’s classification for assessing prognosis in cirrhosis? Aliment Pharmacol Ther. 2005;22(11- 12):1079-89.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>8. Freeman RB Jr, Wiesner RH, Harper A, McDiarmid SV, Lake J, Edwards E, Merion R, Wolfe R, Turcotte J, Teperman L. The new liver allocation system: Moving toward evidence-based transplantation policy. Liver Transpl. 2002;8(9):851-8.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>9. Boursier J, Cesbron E, Tropet AL, Pilette C. Comparison and improvement of MELD and Child-Pugh score accuracies for the prediction of 6-month mortality in cirrhotic patients. J Clin Gastroenterol. 2009;43(6):580-5.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>10. Flores-Rendón AR, González-González JA, García-Compean D, Maldonado-Garza HJ, Garza-Galindo AA. Model for end stage of liver disease (MELD) is better than the Child-Pugh score for predicting in-hospital mortality related to esophageal variceal bleeding. Ann Hepatol. 2008;7(3):230-4.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>11. Lau T, Ahmad J. Clinical applications of the Model for End-Stage Liver Disease (MELD) in hepatic medicine. Hepat Med. 2013;5: 1-10.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>12. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol. 2013;10(9):553-62.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>13. Готье СВ, КонстантиновБА, ЦирульниковаОМ. Трансплантация печени. М.: Медицинское информационное агентство; 2008. (Got’e SV, Konstantinov BA, Tsirul’nikova OM. Liver transplantation. Moscow: Meditsinskoe informatsionnoe agentstvo; 2008. Russian).</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>14. Kohli A, Shaffer A, Sherman A, Kottilil S. Treatment of hepatitis C: a systematic review. JAMA. 2014;312(6):631-40.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>15. Arnaud C, Trépo C, Petit MA. Predictors of the therapeutic response in hepatitis C. A 2013 update. Clin Res Hepatol Gastroenterol. 2014;38(1):12-7.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>16. Di Marco V, Almasio PL, Ferraro D, Calvaruso V, Alaimo G, Peralta S, Di Stefano R, Craxì A. Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial. J Hepatol. 2007;47(4):484-91.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>17. Poordad F, Lawitz E, Reddy KR, Afdhal NH, Hézode C, Zeuzem S, Lee SS, Calleja JL, Brown RS Jr, Craxi A, Wedemeyer H, Nyberg L, Nelson DR, Rossaro L, Balart L, Morgan TR, Bacon BR, Flamm SL, Kowdley KV, Deng W, Koury KJ, Pedicone LD, Dutko FJ, Burroughs MH, Alves K, Wahl J, Brass CA, Albrecht JK, Sulkowski MS; Protocol 6086 Investigators. Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection – a randomized trial. Gastroenterology. 2013;145(5):1035-1044.e5.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>18. Hézode C, Fontaine H, Dorival C, Zoulim F, Larrey D, Canva V, De Ledinghen V, Poynard T, Samuel D, Bourliere M, Alric L, Raabe JJ, Zarski JP, Marcellin P, Riachi G, Bernard PH, LoustaudRatti V, Chazouilleres O, Abergel A, Guyader D, Metivier S, Tran A, Di Martino V, Causse X, Dao T, Lucidarme D, Portal I, Cacoub P, Gournay J; CUPIC Study Group. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology. 2014;147(1): 132-142.e4.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>19. Everson GT, Trotter J, Forman L, Kugelmas M, Halprin A, Fey B, Ray C. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology. 2005;42(2): 255-62.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>20. Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourlière M, Sulkowski MS, Wedemeyer H, Tam E, Desmond P, Jensen DM, Di Bisceglie AM, Varunok P, Hassanein T, Xiong J, PilotMatias T, DaSilva-Tillmann B, Larsen L, Podsadecki T, Bernstein B. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370(17):1604-14.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>21. Chen YC, Chu CM, Yeh CT, Liaw YF. Natural course following the onset of cirrhosis in patients with chronic hepatitis B: a long-term follow-up study. Hepatol Int. 2007;1(1):267-73.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>22. McMahon BJ. Chronic hepatitis B virus infection. Med Clin North Am. 2014;98(1):39-54.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>23. Chen CJ, Yang HI, Iloeje UH; REVEAL-HBV Study Group. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology. 2009;49(5 Suppl):S72-84.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>24. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50(3):661-2.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>25. Shim JH, Lee HC, Kim KM, Lim YS, Chung YH, Lee YS, Suh DJ. Efficacy of entecavir in treatment-naïve patients with hepatitis B virusrelated decompensated cirrhosis. J Hepatol. 2010;52(2):176-82.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>26. Liaw YF, Sheen IS, Lee CM, Akarca US, Papatheodoridis GV, SuetHing Wong F, Chang TT, Horban A, Wang C, Kwan P, Buti M, Prieto M, Berg T, Kitrinos K, Peschell K, Mondou E, Frederick D, Rousseau F, Schiff ER. Tenofovirdisoproxilfumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology. 2011;53(1):62-72.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>27. Liaw YF, Raptopoulou-Gigi M, Cheinquer H, Sarin SK, Tanwandee T, Leung N, Peng CY, Myers RP, Brown RS Jr, Jeffers L, Tsai N, Bialkowska J, Tang S, Beebe S, Cooney E. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. Hepatology. 2011;54(1):91-100.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>28. Lange CM, Bojunga J, Hofmann WP, Wunder K, Mihm U, Zeuzem S, Sarrazin C. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology. 2009;50(6):2001-6.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>29. Peng CY, Chien RN, Liaw YF. Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy. J Hepatol. 2012;57(2):442-50.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>30. Papatheodoridis GV, Cholongitas E, Archimandritis AJ, Burroughs AK. Current management of hepatitis B virus infection before and after liver transplantation. Liver Int. 2009;29(9): 1294-305.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>31. Samuel D. Management of hepatitis B in liver transplantation patients. Semin Liver Dis. 2004;24 Suppl 1:55-62.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>32. Schiff E, Lai CL, Hadziyannis S, Neuhaus P, Terrault N, Colombo M, Tillmann H, Samuel D, Zeuzem S, Villeneuve JP, Arterburn S, Borroto-Esoda K, Brosgart C, Chuck S; Adefovir Dipivoxil Study 45 International Investigators Group. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl. 2007;13(3): 349-60.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>33. Price J. An update on hepatitis B, D, and E viruses. Top Antivir Med. 2014;21(5):157-63.</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>34. Tugui L, Dumitru M, Iacob S, Gheorghe L, Preda C, Dinu I, Becheanu G, Dumbrava M, Nicolae I, Andrei A, Lupu A, Diculescu M. The efficacy of the Peginterferon treatment in chronic hepatitis HDV and compensate liver cirrhosis. Rev Med ChirSoc Med Nat Iasi. 2014;118(2):368-75.</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>35. Heidrich B, Yurdaydın C, Kabaçam G, Ratsch BA, Zachou K, Bremer B, Dalekos GN, Erhardt A, Tabak F, Yalcin K, Gürel S, Zeuzem S, Cornberg M, Bock CT, Manns MP, Wedemeyer H; HIDIT-1 Study Group. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. Hepatology. 2014;60(1):87-97.</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>36. Heller T, Rotman Y, Koh C, Clark S, Haynes-Williams V, Chang R, McBurney R, Schmid P, Albrecht J, Kleiner DE, Ghany MG, LiangTJ, HoofnagleJH. Long-term therapy of chronic delta hepatitis with peginterferon alfa. Aliment Pharmacol Ther. 2014;40(1): 93-104.</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>37. Farci P, Chessa L, Balestrieri C, Serra G, Lai ME. Treatment of chronic hepatitis D. J Viral Hepat. 2007;14 Suppl 1:58-63.</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>38. Yurdaydın C, Idilman R, Bozkaya H, Bozdayi AM. Natural history and treatment of chronic delta hepatitis. J Viral Hepat. 2010;17(11):749-56.</mixed-citation></ref></ref-list></back></article>
